Inhibrx director trust sells 1,500 shares
A director-related trust reported selling 1,500 INBX common shares over three days in mid-September 2026.
Rhea-AI Filing Summary
Inhibrx Biosciences, Inc. (INBX) reported that director Kimberly Manhard, through the Kimberly Joan Manhard Revocable Trust dated June 4, 2012, sold a total of 1,500 shares of common stock in open market or private transactions on September 11, 14, and 15, 2026 at prices between $105.05 and $111.78 per share. The sales were reported as indirect ownership transactions by the trust, for which Ms. Manhard may be deemed to beneficially own the securities as trustee.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 1,500 shares
Net Sell
3 txns
Insider
MANHARD KIMBERLY
Role
Director
Sold
1,500 shs ($164K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 500 | $105.05 | $53K |
| Sale | Common Stock F1 | 500 | $110.26 | $55K |
| Sale | Common Stock F1 | 500 | $111.775 | $56K |
Holdings After Transaction:
Common Stock — 7,500 shares (Indirect, Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012)
Footnotes (1)
- F1. These securities are directly owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. Kimberly Manhard is a trustee of the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012.
Key Figures
Total shares sold: 1,500 shares
Sale price on September 11, 2026: $111.7750 per share
Sale price on September 14, 2026: $110.2600 per share
+1 more
4 metrics
Total shares sold
1,500 shares
Aggregate common shares sold by the Manhard trust in September 2026 transactions
Sale price on September 11, 2026
$111.7750 per share
500 INBX common shares sold indirectly by the Manhard trust
Sale price on September 14, 2026
$110.2600 per share
500 INBX common shares sold indirectly by the Manhard trust
Sale price on September 15, 2026
$105.0500 per share
500 INBX common shares sold indirectly by the Manhard trust
Key Terms
indirectly beneficially own, Revocable Trust, open market or private transaction
3 terms
indirectly beneficially own financial
"may be deemed to indirectly beneficially own the securities owned by"
Revocable Trust financial
"These securities are directly owned by the Kimberly Joan Manhard Revocable Trust"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
open market or private transaction financial
"Sale in open market or private transaction"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider trading activity did INBX disclose in this Form 4?
The filing reports that a trust associated with director Kimberly Manhard sold 1,500 shares of Inhibrx Biosciences common stock in three separate transactions on September 11, 14, and 15, 2026.
Is the insider trading in INBX under a Rule 10b5-1 trading plan?
No Rule 10b5-1 trading plan is indicated. The document-level checkbox for Rule 10b5-1 is unchecked, and the footnotes do not describe any pre-arranged trading plan for these transactions.
Are the INBX sales reported as direct or indirect ownership changes?
All three transactions are reported as changes in indirect ownership, because the common stock is held by the Kimberly Joan Manhard Revocable Trust rather than directly by Kimberly Manhard.
AI-generated analysis. How Rhea-AI works. Not financial advice.